Shanghai Xuerong Bio-Technology changes ownership, new actual controller sets a "hundred billion Market Cap" flag | Quick read announcement.

① The control of Shanghai Xuerong Bio-Technology has changed, with chairman Yang Yongping relinquishing the position of the company's controlling Shareholder and actual controller. ② Jiang Zhi, an entrepreneur from the Online Games industry, will become the new actual controller. He stated that he hopes to build Shanghai Xuerong Bio-Technology into a publicly traded company with a revenue of 10 billion and a Market Cap of 100 billion in the next 3 to 5 years.

cls.cnMar 12 21:49 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.

① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.

cls.cnJan 5 19:05 ET

Xiwang Foodstuffs Vice Chairman Sun Xinguo: The scale of the rapeseed oil business is expanding, and the sports nutrition product business is in a transformation stage. | Interview with Finance Specialist

①With the decline in prices of raw materials such as corn and protein, xiwang foodstuffs achieved high growth in performance in the first three quarters. The fourth quarter is the traditional peak season for corn oil, and it is expected that profits will further improve. ②The company's sports nutrition business has begun to grow steadily. In the first half of this year, the revenue share of xiwang foodstuffs' sports nutrition business accounted for nearly half, with a gross margin of 30.47%. The company plans to develop 2-3 major single products within two years.

cls.cnNov 8, 2024 09:14 ET

The pesticide market downturn dragged aba chemicals corporation into losses for five consecutive quarters, but the amount of losses narrowed. Interpretations of financial statements.

①Aba Chemicals Corporation has been operating at a loss for five consecutive quarters in Q3, but the amount of loss has narrowed compared to the first two quarters of this year. ② The pesticide industry is still at a low level, and the market situation for the company's main product, chlorfenapyr intermediate, has dropped significantly within one year. ③ The company's top ten shareholders changed in Q3, with a new institution shareholder and 'northbound funds' entering.

cls.cnOct 23, 2024 11:16 ET

Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations

①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.

cls.cnAug 23, 2024 08:58 ET